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Abstract
Chikungunya virus (CHIKV) is an alphavirus responsible for numerous epidemics throughout Africa and Asia, causing
infectious arthritis and reportedly linked with fatal infections in newborns and elderly. Previous studies in animal
models indicate that humoral immunity can protect against CHIKV infection, but despite the potential efficacy of B-
cell-driven intervention strategies, there are no virus-specific vaccines or therapies currently available. In addition,
CHIKV has been reported to elicit long-lasting virus-specific IgM in humans, and to establish long-term persistence in
non-human primates, suggesting that the virus might evade immune defenses to establish chronic infections in man.
However, the mechanisms of immune evasion potentially employed by CHIKV remain uncharacterized. We previously
described two human monoclonal antibodies that potently neutralize CHIKV infection. In the current report, we have
characterized CHIKV mutants that escape antibody-dependent neutralization to identify the CHIKV E2 domain B and
fusion loop ‘‘groove’’ as the primary determinants of CHIKV int e r a c t i o nw i t ht h e s ea n t i b o d i es. Furthermore, for the first
time, we have also demonstrated direct CHIKV cell-to-cell transmission, as a mechanism that involves the E2 domain A
and that is associated with viral resistance to antibody-dependent neutralization. Identification of CHIKV sub-domains
that are associated with human protective immunity, will pave the way for the development of CHIKV-specific sub-
domain vaccination strategies. Moreover, the clear demonstration of CHIKV cell-to-cell transmission and its possible
role in the establishment of CHIKV persistence, will also inform the development of future anti-viral interventions.
These data shed new light on CHIKV-host interactions that will help to combat human CHIKV infection and inform
future studies of CHIKV pathogenesis.
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Introduction
Chikungunya virus (CHIKV) belongs to the alphavirus genus of
the Togaviridae family and is transmitted to humans by Aedes
mosquitoes. CHIKV was first isolated in Tanzania in 1952 [1],
with numerous outbreaks subsequently being reported throughout
Africa and Asia. Within the last decade, a large CHIKV epidemic
has spread from the Indian Ocean islands to India and South-East
Asia [2,3]. Moreover, cases of CHIKV infection have since been
detected both in Italy, in 2007 [4,5], and in France, in 2010 [6],
indicating that CHIKV has now become an infectious threat that
is no longer limited to tropical areas.
While CHIKV infection in humans is often associated with only
mild clinical symptoms that resolve over 1–2 weeks [7], there have
also been reports of prolonged joint pain [8,9], active and
destructive rheumatoid arthritis [10], and severe encephalopathic
events in neonates [11]. Despite the increasing burden of infection
in Africa and Asia, and the recent advance of CHIKV into
European territories, specific therapies for CHIKV-infected
patients are not yet available [12].
CHIKV exhibits a positive strand RNA genome that encodes 4
non-structural proteins (NSP1–4) and 5 structural proteins: the
capsid (C), the E1, E2, and E3 envelope glycoproteins (E2 and E3
are initially synthesized as a single precursor molecule, p62, which
is subsequently cleaved), and a small polypeptide molecule, 6K
[13]. However, the mature CHIKV virion is comprised only of the
C, E1 and E2 proteins, which encapsulate the virus genome [13–
15]. The E1 and E2 proteins control viral entry into host cells: E1
mediates virus fusion to cell membranes in low pH conditions
[16,17], while E2 interacts with a cellular receptor [18,19]. These
constituent proteins of CHIKV virion mediate virus dissemination,
therefore specific targeting of these structures will be key to the
future development of effective CHIKV vaccination strategies.
The structure of the E1 protein in alphaviruses has previously
been determined using the representative Semliki Forest virus
family member [20,21]. More recently, the crystal structure of the
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under neutral pH conditions (using CHIKV: [22]), and at acidic
pH (using Sindbis virus: [23]) thus further clarifying the structural
composition of the alphaviruses. The alphavirus E1 ectodomain
comprises three separate sub-domains; the N-terminal domain I
(central to the 3D structure of E1), the domain II (located at the
distal tip of the ectodomain) containing the fusion peptide residues
83–98, and the C-terminal domain III (located close to the viral
membrane). The E2 ectodomain also contains three distinct sub-
domains; the N-terminal domain A (central to the 3D structure of
E2), the domain B - located at the distal tip of the ectodomain and
that may interact with a cellular receptor, and the C-terminal
domain C (located close to the viral membrane).
Human antibodies isolated from the plasma of a CHIKV
convalescent patient have previously been shown to both prevent
and cure CHIKV infection in mice [24], suggesting that
neutralizing antibody responses might be capable of efficiently
controlling CHIKV infection in humans. Although the brief
viremia associated with CHIKV infections is suggestive of rapid
viral clearance, several recent reports have instead detected long-
lasting CHIKV-specific IgM, suggesting that viral antigens may in
fact persist in humans [25,26]. Moreover, long-term survival of
CHIKV in macrophages has also been reported in non-human
primates [27], indicating that CHIKV might establish chronic
infections that evade immune defenses.
Viruses can escape neutralizing antibody responses by under-
going genetic mutations that abolish antibody binding, or by
indirect evasion strategies such as cell-to-cell transmission. It is
currently unclear whether CHIKV is capable of exploiting these
strategies to persist in human hosts.
In this study, we aimed to characterize CHIKV antigens
targeted by neutralizing human antibodies to inform the
subsequent design of CHIKV-specific sub-domain vaccination
strategies. We also sought to identify potential mechanisms of
immune evasion that CHIKV might exploit to establish persistent
infections in man. We recently identified two human monoclonal
antibodies (mAb), designated 5F10 and 8B10, which broadly and
potently neutralize CHIKV in vitro [28]. In the current report, we
analyzed neutralization-resistant CHIKV mutants to identify the
E2 domain B and the fusion loop ‘‘groove’’ as the primary
determinants of CHIKV interaction with 5F10 and 8B10,
respectively. Furthermore, we provide evidence that CHIKV
can be efficiently transmitted from cell to cell in a manner that
depends on E2 domain A, and that is associated with resistance to
antibody-dependent neutralization. Taken together, these data
advance our understanding of CHIKV-human host interactions
and will inform future efforts to combat this viral disease.
Results
Selection of CHIKV mutants escaping antibody-
dependent neutralization
We recently identified two human mAb designated 5F10 and
8B10, which broadly and potently neutralize CHIKV in vitro (28).
In order to identify the neutralization antigens that are targeted by
these mAb, we subjected a CHIKV clinical isolate (CHIKV11) to
8 rounds of amplification under the continuous neutralizing
pressure of mAb 5F10, 8B10, 5F10+8B10, or an irrelevant isotype-
matched control (Irr.IgG1), before isolating viruses CHIK/5F,
CHIK/8B, CHIK/5F+8B, and CHIK/Irr, respectively. When
assessed in a Plaque Reduction Neutralization Test (PRNT),
CHIK/Irr was efficiently neutralized by 5F10 and 8B10, either by
each mAb independently, or by both mAb used in combination,
whereas CHIK/5F was not neutralized by 5F10 (Figure 1).
CHIK/8B and CHIK/5F+8B were less efficiently neutralized by
8B10 and 5F10+8B10 respectively than the CHIK/Irr control
(Figure 1). These data indicated that CHIK/5F was resistant to
5F10 neutralizing activity, while CHIK/8B and CHIK/5F+8B
were partially resistant to 8B10 and 5F10+8B10 neutralizing mAb.
To investigate whether CHIKV resistance to mAb 5F10 and/or
8B10 was associated with specific mutation(s), viral RNA was
isolated from each CHIKV mutant and reverse-transcribed into
cDNA for sequencing. When compared with the CHIK/Irr
control genome, we identified two nucleotide (nt) substitutions
within the CHIK/5F genome that resulted in amino acid (aa)
changes at positions 82 and 216 in the E2 protein (E2.R82G and
E2.V216E). In the CHIK/8B genome, we identified one nt
substitution that resulted in an aa change at position 101 in the E1
protein (E1.T101M), and also observed 1 mix of wild-type (wt)/
mutated nt, with the mutated nt leading to one aa change at
position 12 of E2 (E2.T12I). We detected only one nt substitution
in the CHIK/5F+8B genome, which generated the same
E2.R82G substitution as previously identified in CHIK/5F
genome (Table 1). We did not identify any mutations within the
C, E3 or 6K protein-encoding sequences.
Intriguingly, the mutated nts associated with the residue
substitutions E1.T101M, E2.T12I, E2.R82G and E2.V216E were
also detectable in the polyclonal CHIK/Irr control cDNA
preparation (Table 2), although their proportion was extremely
low (0.05–0.20% of the total nts at each position). This suggests
that minor pre-existing CHIKV quasi-species were amplified
under selective pressure from CHIKV-neutralizing mAb.
Key amino acid substitutions in the E1 and E2 proteins
that confer CHIKV resistance to antibody-dependent
neutralization
To investigate the roles of the different CHIKV mutations in
mediating resistance to mAb 5F10 and 8B10, we isolated CHIKV
clones that exhibited either single or dual mutations and then
further probed their sensitivity to mAb-dependent neutralization.
Author Summary
Chikungunya virus (CHIKV) is transmitted by mosquito
bites and causes a febrile disease that is often character-
ized by persistent joint pain. Until recently, CHIKV
outbreaks were limited to tropical areas of Africa and
Asia. However, since 2007, following a large CHIKV
epidemic in the Indian Ocean and South-East Asia, CHIKV
has also been reported in temperate European regions. As
mosquito habitats expand, virus dissemination may
become more prevalent, but there are currently no
vaccines or CHIKV-specific treatments available. We
previously described two human antibodies that potently
block cellular CHIKV infection. In the current report, we
have characterized CHIKV mutants that escape neutraliza-
tion to identify sub-domains of the virus envelope which
are involved in CHIKV interaction with these antibodies,
thereby opening the door for the development of CHIKV-
specific sub-domain vaccination strategies. For the first
time, we have also demonstrated that CHIKV can be
directly transmitted between cells, bypassing transport
through the extra-cellular space. This mode of dissemina-
tion, which is associated with viral resistance to antibody
neutralization, may play a critical role in the establishment
of persistent CHIKV infection. Together, these findings will
aid the design of new strategies to combat CHIKV infection
and will inform future studies of CHIKV pathogenesis.
CHIKV Neutralization-Escape Mutants
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before 6 individual CHIK/5F, CHIK/8B, or CHIK/5F+8B
colonies (or 2 CHIK/Irr control colonies) were isolated for
amplification and sequencing. The sequencing data from the
plaque-purified CHIKV clones are shown in Table 3. The 6
CHIK/5F-derived clones contained both the E2.R82G and
E2.V216E mutations. One of the CHIK/5F-derived clones also
Figure 1. Reduced neutralizing potency of mAb 5F10 and 8B10 against CHIKVs amplified under selective pressure. CHIK/Irr, CHIK/5F,
CHIK/8B and CHIK/5F+8B indicate CHIKV rescued from 8 serial cell passages under the continuous mAb pressure of Irr.IgG1, 5F10, 8B10 and
5F10+8B10, respectively. (A) The neutralizing potency of CHIKV-specific mAb was evaluated in PRNT over a concentration range of 1 ng-100 mg/ml.
Displayed are the mean and SEM from 3 independent experiments performed in duplicate, with non-linear regression fitting curves. Regression could
not be calculated for CHIK/5F due to non convergence. (B) The extrapolated IC50 from 2 or 3 independent experiments are shown, alongside the
mean and SEM.
doi:10.1371/journal.ppat.1002390.g001
Table 1. Amino acid variations in the E1 and E2 glycoproteins
among CHIKV variants amplified over 8 rounds under mAb
pressure.
CHIKVs E1
a E2
b
101 12 82 216
CHIK/Irr T T R V
CHIK/5F T T GE
CHIK/8B MT / I RV
CHIK/5F+8B T T G V
a,bNumbers refer to the aa positions within the E1 and E2 CHIKV proteins,
respectively. The aa variations associated with the CHIKV-specific mAb are
highlighted in bold.
doi:10.1371/journal.ppat.1002390.t001
Table 2. Next Generation Sequencing of non-clonal CHIK/Irr
after 8 rounds under mAb pressure.
aa
substitution
a
nt
substitution
b
number
of reads
c nt (%)
d
ATCG
E2.T12I C1010T 7907 0.10 0.08 99.71 0.11
E2.R82G A1219G 7826 99.58 0.04 0.18 0.20
E2.V216E T1622A 7840 0.05 99.55 0.31 0.09
E1.T101M C2729T 7999 0.14 0.09 99.76 0.01
aNumbers refer to the aa position within the indicated protein, E1 or E2.
bNt substitutions associated with aa substitutions indicated in
a.
Numbers refer to the nt position within the C-E1 encoding sequence.
cIndicates the number of sequenced viral cDNA copies, as performed by Next
Generation Sequencing.
dIndicates the percentage of each nt identified at each position.
doi:10.1371/journal.ppat.1002390.t002
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membrane domain (T396A and I427T). Five of the CHIK/8B-
derived clones contained both the E1.T101M and E2.T12I
mutations, while another CHIK/8B-derived clone contained the
E1.T101M mutation alone. All 6 CHIK/5F+8B-derived clones
contained the E2.R82G mutation. Hereafter, the 5F10-derived
clonal viruses are designated 5F/E2.R82G+V216E and 5F/
E1.TMm+E2.R82G+V216E, the 8B10-derived virus mutants as
8B/E1.T101M and 8B/E1.T101M+E2.T12I, and the 5F10+
8B10-derived virus, as 5F+8B/E2.R82G. The Irr.IgG1-derived
clonal virus is designated CHIKwt.
In PRNT assays, mAb 5F10 neutralized 5F/E2.R82G+V216E
and 5F/E1.TMm+E2.R82G+V216E far less efficiently than
CHIKwt (Figure 2). There were no significant differences between
the two mutants, suggesting that neither of the two mutations in
E1 had any effect on the neutralization potency of mAb 5F10.
Although high concentrations of mAb 5F10 did not neutralize the
CHIKV mutant containing E2.R82G alone (5F+8B/E2.R82G) as
efficiently as CHIKwt, there was no significant difference in IC50
between 5F+8B/E2.R82G and CHIKwt, suggesting only a
minimal effect of the mutation E2.R82G on 5F10-dependent
CHIKV neutralization. Together, these data suggest a key role for
the E2.V216E mutation in mediating CHIKV resistance to 5F10-
dependent neutralization.
In parallel, mAb 8B10 neutralized 8B/E1.T101M less efficient-
ly than CHIKwt (Figure 2), indicating a contribution for the
mutation E1.T101M in mediating CHIKV resistance to 8B10-
dependent neutralization. However, the viral mutant 8B/
E1.T101M was more efficiently neutralized by mAb 8B10 than
the dual mutant 8B/E1.T101M+E2.T12I (Figure 2), demonstrat-
ing that both the E1.T101M and E2.T12I mutations confer
CHIKV resistance to 8B10-dependent neutralization.
Interestingly, the 8B10-derived CHIKV mutants remained
efficiently neutralized by mAb 5F10, and vice versa (Figure 2). Thus,
the binding sites of 5F10 and 8B10 are most likely different.
As the two mutations in the E1 trans-membrane domain were
not associated with resistance to mAb-dependent neutralization,
5F/E1.TMm+E2.R82G+V216E was excluded from further anal-
yses. Although the E2.R82G mutation was not found to be
associated with significant resistance to mAb-dependent neutral-
ization in PRNT assay, as this was the only mutation to be selected
under dual treatment with mAb 5F10 and 8B10 (Tables 1 and 3),
It was hypothesized that this mutation might be associated with a
CHIKV immune evasion mechanism which was not detectable by
PRNT assay. We therefore retained the 5F+8B/E2.R82G mutant
for analysis in subsequent experiments.
E2.V216E and E1.T101M abolish the binding of 5F10 and
8B10 to CHIKV
To clarify the mechanism(s) associated with the neutralization
escape mutations, we next analyzed the capacity of mAb 5F10 and
8B10 to bind to clonal CHIKVs (Figure 3).
Binding tests performed on CHIKV-infected cells (Figure 3A
and 3B) and on CHIKV particles (Figure 3C) showed that the
binding of 5F10 to 5F/E2.R82G+V216E was drastically impaired,
whereas 5F10 efficiently bound the single mutant 5F+8B/
E2.R82G. The binding of 8B10 to both 8B/E1.T101M and
8B/E1.T101M+E2.T12I was severely impeded. Interestingly,
5F10-derived mutated viral particles remained bound by 8B10
and vice versa (Figure 3C), confirming that mAb 5F10 and 8B10
exhibit distinct epitope specificities. However, binding assays
performed on infected cells showed that 5F10-derived viruses were
less efficiently bound by 8B10 when compared with CHIKwt
(Figure 3A and 3B). These data are consistent with our previous
suggestion that the target epitope for 8B10 was likely to be
conformation-dependent [28]. It is therefore possible that, while
expressed in infected cells and under experimental conditions used
for the binding test on infected cells, the 8B10 epitope is indirectly
modified by substitution of distantly located residues, such as
E2.82 or E2.216.
Taken together, these data demonstrate that mutations
E2.V216E and E1.T101M abolish the binding of mAb 5F10
and 8B10 to CHIKV, respectively.
Structural location of key amino acid residues in the
alphavirus E1/E2 glycoprotein
To further clarify the CHIKV domains involved in virus
interaction with mAb 5F10 and 8B10, we used Chimera software
to locate residues E1.101, E2.12, E2.82 and E2.216 within the
CHIKV E1/E2 heterodimer for which the crystal structure was
recently resolved under neutral pH conditions [22] (Figure 4).
The E2.82 residue is exposed at the surface of the E2 domain A
(Figure 4A), while the E2.216 residue is found at the tip of the E2
domain B (Figure 4A), in a position easily accessible to antibody
binding.
The E1.101 residue is located within the E1 domain II next to
the fusion loop (Figure 4B), suggesting that mAb 8B10 might target
the fusion peptide itself. However, under neutral pH conditions,
the exposed surface of the native viral particle is largely comprised
of the E2 domains A and B, whereas the E1 protein remains
concealed beneath the E2 protein, and its fusion peptide fits into a
‘‘groove’’ which is delineated by E2 domains A and B [22].
Therefore, under neutral pH conditions, E1.101 is unlikely to be
accessible to antibody binding.
The E2.12 residue, which is involved in resistance to 8B10-
dependent neutralization together with E1.101 (Figure 2), is
located within the E2 domain A, directly above the ‘‘groove’’
which incorporates E1.101 (Figure 4B).
Noteworthy, under acidic pH conditions, the alphavirus domain
B becomes disordered and releases the fusion loop [23].
Interestingly, on the E2/E1 spatial arrangement of Sindbis virus
(closely related with CHIKV) resolved under acidic pH conditions
[23], the residues E1.101 and E2.12 are located on the internal
side of the opened ‘‘groove’’, facing each other (Figure 5). This
suggests that after virus internalization into host cell and within the
acidic endosomal compartment, the residues E1.T101 and E2.T12
(corresponding to Sindbis virus E1.S101 and E2.T9) may become
Table 3. Amino acid variations in the E1 and E2 glycoproteins
among clonal CHIKVs.
Clonal CHIKV E1
a E2
b
101 396 427 12 82 216
CHIK/5F #1,3, 4, 5 and 6 T T I T GE
CHIK/5F #2T ATT GE
CHIK/8B #1,3, 4, 5 and 6 M TI I RV
CHIK/8B #2 M TI T R V
CHIK/5F+8B #1 - 6 TTI T G V
CHIK/Irr #1 - 2 TTI T R V
a,bNumbers refer to the aa positions within the E1 and E2 CHIKV glycoproteins,
respectively. The aa variations associated with the CHIKV-specific mAb are
highlighted in bold.
doi:10.1371/journal.ppat.1002390.t003
CHIKV Neutralization-Escape Mutants
PLoS Pathogens | www.plospathogens.org 4 December 2011 | Volume 7 | Issue 12 | e1002390Figure 2. 5F10 and 8B10 mAb neutralizing potency against clonal CHIKVs. CHIKV variants have been labelled according to their residue
substitutions and corresponding mAb added to the culture medium during the serial passages. (A) Neutralizing capacities of the mAb against
plaque-purified CHIKV were evaluated in PRNT over a concentration range of 1 ng-100 mg/ml. Shown are the mean and SEM from 4 independent
CHIKV Neutralization-Escape Mutants
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transitional epitope.
Taken together, these structural data strongly suggest that the
5F10 epitope is located at the tip of the CHIKV E2 domain B
which contains the E2.216 residue. While the 8B10 target antigen
remains somewhat ambiguous, our data suggest that this antibody
may recognize a transitional epitope closely associated with the
CHIKV fusion peptide.
Fitness characteristics of the CHIKV E2.R82G mutant
suggest viral cell-to-cell transmission
The alignment of available CHIKV E1 and E2 protein
sequences obtained from GeneBank (data not shown) indicated
that all published CHIKV variants contain the residues E1.T101,
E2.T12, E2.V216 and E2.G82, except for one strain: TSI-GSD-
218, which contains E2.I12 and E2.R82. Thus, among the
mutations selected here, E1.T101M, E2.T12I and E2.V216E
clearly modify highly conserved CHIKV residues, while E2.R82G
instead restores a highly conserved viral residue. These data
indicate that the CHIKV11 isolate used in the current study is
atypical with regards to the E2.82 residue, and suggest an
important role for the E1.T101, E2.T12, E2.G82 and E2.V216
residues in the CHIKV life cycle. Therefore, the substitution of
these conserved residues was expected to modify CHIKV fitness,
and thus, we next investigated fitness characteristics of 5F10/
8B10-resistant CHIKV escape mutants.
We first assessed the in vitro extra-cellular spreading of the mAb-
resistant CHIKV mutants. Vero cells were infected with clonal
CHIKVs, and viral titer was next determined by Plaque Assay and
expressed as the number of Plaque Forming Units (PFU) per mL
of cell culture supernatant. Over the 48 h growth period, all
CHIKV escape mutants led to significant decreases in PFU
number, when compared with CHIKwt (Figure 6A). These results
demonstrate that CHIKV variants which escape 5F10- and/or
8B10-dependent neutralization are impaired in extra-cellular viral
spreading in vitro.
We next investigated the in vivo fitness of the CHIKV
neutralization-escape mutants. AGR129 immuno-compromised
mice [29] were used to determine survival after infection with the
different clonal CHIKVs (Figure 6C). Mice infected with 8B/
E1.T101M were indistinguishable from control mice infected with
CHIKwt, suggesting that the E1.T101M mutation does not
interfere with CHIKV fitness in vivo. In contrast, death among
mice infected with 8B/E1.T101M+E2.T12I was delayed, when
compared with mice infected with CHIKwt, suggesting that the
E2.T12I mutation impairs CHIKV fitness in vivo. Interestingly,
mice infected with 5F+8B/E2.R82G or 5F/E2.R82G+V216E
died significantly earlier than those infected with other CHIKV
variants. However, no difference was observed between mice
infected with either 5F+8B/E2.R82G or 5F/E2.R82G+
E2.V216E, suggesting that the E2.R82G mutation is entirely
responsible for the rapid post-infection mortality, and that the
E2.V216E mutation does not alter in vivo CHIKV fitness.
Mice were next infected with either CHIKwt or 5F+8B/
E2.R82G and viral load was determined in serum and liver at
48 h post-infection (Figure 6D), alongside quantification of
CHIKV (-) RNA in liver (Figure 6E). In both liver and serum,
viral load of 5F+8B/E2.R82G was significantly higher than that
of CHIKwt, with the largest difference (,1000-fold) being
observed in serum (Figure 6D). Likewise, the number of
5F+8B/E2.R82G (-) RNA copies in liver was ,10-fold higher
than for CHIKwt (Figure 6E). These data demonstrated that 48 h
post-infection, the level of 5F+8B/E2.R82G replication was
higher than that of CHIKwt. Moreover, a previous study in an
alternative murine model of immunodeficiency reported that
CHIKV is detected in the liver prior to being detected in the
serum [30]. Therefore, our data suggest that 5F+8B/E2.R82G
spreads faster in vivo than CHIKwt, since CHIKwt load was
reduced in serum compared with liver, while the 5F+8B/
E2.R82G load was comparable in both tissues (Figure 6D). The
enhanced in vivo fitness of 5F+8B/E2.R82G supports an
important role for the E2.G82 residue in CHIKV life cycle,
which may explain the high conservation of this residue among
CHIKV strains described as of now.
Since measuring the relative size of virus-induced plaques is
commonly performed to monitor viral cell-to-cell transfer [31–33],
we were intrigued to observe that 5F+8B/E2.R82G and 5F/
E2.R82G+V216E gave rise to bigger plaques compared with
alternative CHIKV variants (Figure 6B). This ‘‘big plaques’’
phenotype, together with the impaired in vitro extra-cellular viral
spreading (Figure 6A), suggested that CHIKV might disseminate
directly from cell to cell, in a manner induced or enhanced by the
mutation E2.R82G. Interestingly, the rapid in vivo spreading of
5F+8B/E2.R82G when compared with CHIKwt (Figure 6C–6E),
further suggested an E2.R82G-associated CHIKV cell-to-cell
transmission, as this mode of dissemination is considered to be
faster than extra-cellular transmission [34].
CHIKV cell-to-cell transmission is enhanced by E2.R82G
Direct cell-to-cell transmission was previously proposed to occur
during CHIKV infection in vitro [35], but formal demonstration of
this mode of dissemination has been lacking. To address this
possibility, unlabeled HEK293T cells were infected with either
CHIKwt or 5F+8B/E2.R82G. Ten hours post-infection, the
infected cells (producer cells) were co-cultured with CFSE-labeled
non-infected HEK293T cells (target cells), in the presence or
absence of mAb 8B10. After 0 h and 16 h of co-culture, the
number of CHIKV-infected cells was determined by flow-
cytometry (Figure 7A). By 16 h, the majority of target cells
(47.0% and 51.1% for CHIKwt and 5F+8B/E2.R82G, respec-
tively) were CHIKV-infected when cultured without mAb 8B10.
Interestingly, even in the presence of 8B10 neutralizing pressure,
the mean proportion of infected target cells was 11.7% for
CHIKwt and 20.6% for 5F+8B/E2.R82G. We therefore hypoth-
esized that these cells had either been infected by direct CHIKV
cell-to-cell transmission, or by 8B10-resistant extra-cellular
CHIKV particles. However, in the presence of mAb 8B10,
extra-cellular CHIKV particles were undetectable in the 5F+8B/
E2.R82G-derived supernatants, and only an extremely low titer
was measured in CHIKwt-derived supernatants (Figure 7B),
demonstrating that, under 8B10 neutralizing pressure, target cells
infection resulted from CHIKV direct cell-to-cell transmission.
Moreover, the significant higher percentage of infected target cells
detected with 5F+8B/E2.R82G as compared with CHIKwt
indicates that CHIKV cell-to-cell transmission is enhanced by
the E2.R82G mutation.
To further confirm direct cell-to-cell transmission of CHIKV,
some co-cultures were visualized by confocal microscopy. For both
experiments performed in duplicate with non-linear regression fitting curves. (B) The calculated IC50 from 3 or 4 independent experiments and mean
6 SEM are shown (P-values were calculated using Kruskal-Wallis test and Dunn’s post-test, and compare with the IC50 against CHIKwt: *, p,0.05; ***,
p,0.001).
doi:10.1371/journal.ppat.1002390.g002
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PLoS Pathogens | www.plospathogens.org 6 December 2011 | Volume 7 | Issue 12 | e1002390Figure 3. Analysis of 5F10 and 8B10 mAb binding to clonal CHIKVs. (A) Analysis of mAb binding to CHIKV-infected cells by
immunofluorescence assay. HEK293T cells either non-infected, or infected with the indicated CHIKVs, were probed with mAb 5F10, 8B10, anti-CHIKV
plasma, or with irrelevant IgG1. Images were captured at 1006magnification. (B) Quantitative analysis of mAb binding to CHIKV-infected cells by
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CHIKV staining was detected uniformly on the cell surface,
whereas, under 8B10 neutralizing pressure, CHIKV staining was
strongly polarized and virus was often detected in areas of cell-cell
contact (Figure 8). These data strongly suggest that, when the virus
is subjected to antibody dependent-neutralizing pressure, CHIKV
dissemination occurs by direct cell-to-cell transfer at areas of cell
membrane contact. Although these results further show that
CHIKwt can also disseminate by direct cell-to-cell transfer, as less
CHIKV-specific staining was detected in target cells with
Cellomics ArrayScan. HEK293T cells, either mock infected or infected with the indicated CHIKVs, were probed with mAb 5F10, 8B10, anti-CHIKV
plasma, or with irrelevant IgG1. Images were captured at 106 magnification. Displayed are mean fluorescent intensity (MFI) and SEM from 3
independent experiments performed in quadruplicate (P-values were calculated by Kruskal-Wallis test and Dunn’s post-test, and compare with the
MFI of CHIKwt-infected cells: *, p,0.05; **, p,0.01; ***, p,0.001). (C) ELISA analysis of mAb binding to plaque-purified CHIKV particles. ELISA plates
were coated with 10
4 UV-inactivated CHIKV particles, prior to being incubated with mAb (0.1 ng-100 mg/mL). Bound mAb were detected using HRP-
conjugated goat anti-human IgG and TMB substrate. The OD was measured at 450 nm. Shown are mean and SEM from 3 independent experiments
performed in duplicate.
doi:10.1371/journal.ppat.1002390.g003
Figure 4. Location of E1.101, E2.12, E2.82 and E2.216 in the CHIKV E1/E2 heterodimer. Based on structural data retrieved from protein
database records, the 3D organization of E1 (pale yellow), E2 (white), and the E1 fusion loop (pink) are shown for 3N44 under neutral pH conditions.
(A) Front view of E2 with the location of E2.216 (green) and E2.82 (orange). (B) Back left view of E2 and E1 with the location of E2.12 (blue) and E1.101
(red).
doi:10.1371/journal.ppat.1002390.g004
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confirm that the E2.R82G mutation enhances CHIKV cell-to-cell
transmission.
Discussion
We previously demonstrated potent in vitro neutralization of
CHIKV using human mAbs 5F10 and 8B10 [28]. In the current
report, we have characterized CHIKV variants that escape 5F10
and/or 8B10-dependent neutralization to identify the CHIKV E2
domain B and the fusion loop ‘‘groove’’ as the primary
determinants of CHIKV interaction with these neutralizing
antibodies. We have also demonstrated CHIKV cell-to-cell
transmission, which involves the E2 domain A, and may represent
a route by which the virus evades antibody-dependent neutrali-
zation.
Escape mutants have previously been described for three
members of the alphavirus family; Sindbis virus [19,36–38], Ross
River virus [39] and Venezuelan Equine Encephalitis virus [40–
42]. Several neutralization escape mutations have been identified
within the alphavirus E2 domain A [37,40] and domain B
[19,39,40], as well as within the E1 domain II [40]. However,
CHIKV mutants that escape antibody-dependent neutralization
have not previously been reported, and the alphavirus residues
E1.101 and E2.12 were not previously shown to be determinants
of neutralizing antibodies binding. Consistent with the current
report, the E2.216 residue has previously been identified as being
involved in major B-cell neutralization epitopes for Sindbis virus,
Ross River virus and Venezuelan Equine Encephalitis virus
[19,39,40], suggesting that the region covering the E2.216 residue
within the E2 domain B is an important antigenic domain shared
by several alphaviruses. Of note, Coffey and Vignuzzi recently
described mutations that affect the CHIKV E2 residues 229–234
as being due to selective pressure from neutralization [43]. These
mutations affected the C-terminal end of the E2 domain B, as well
as the ß-ribbon connector which links the domain B to the
domains A and C [22,23]. Although these mutations were not
formally shown to be responsible for CHIKV resistance to
neutralization [43], their location is consistent with a crucial role
for the CHIKV E2 domain B in virus-neutralizing antibody
interactions.
Our results strongly suggest that the 5F10 mAb epitope is
located at the tip of the CHIKV E2 domain B, while 8B10 might
recognize a transitional epitope, close to the fusion loop, which is
likely to be exposed under acidic pH conditions. Interestingly, in
addition to the disordering of the alphavirus envelope at acidic
pH, virus binding to a host cellular receptor is believed to induce
pH-independent shifting of the E2 domain B, leading to exposure
of transitional epitopes prior to virion internalization
[22,23,36,44]. We therefore speculate that 8B10 mAb epitope
might be accessible to antibody binding before virus internaliza-
tion into host cell but upon CHIKV binding to a cellular receptor.
Based on their proposed epitope specificity, we speculate that
5F10 and 8B10 inhibit viral entry and fusion to the cell
membrane, respectively. However, it has also been suggested that
antibodies which target the E2 domain B might also affect the
viral-cell fusion step, possibly by inhibiting domain disordering
and fusion loop exposure [23]. Thus 5F10 might alternatively
inhibit virus-cell membrane fusion instead of overtly inhibiting
viral entry.
Figure 5. Location of Sindbis virus residues E1.S101 (CHIKV E1.T101) and E2.T9 (CHIKV E2.T12) in the E1/E2 heterodimer. Indicated
residues were located based on structural data retrieved from protein data base records (3MUU, under acidic pH conditions).
doi:10.1371/journal.ppat.1002390.g005
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PLoS Pathogens | www.plospathogens.org 10 December 2011 | Volume 7 | Issue 12 | e1002390Although RNA viruses are usually prone to high nucleotide
sequence evolution due to their lack of a proofreading polymerase
[45–47], arboviruses seem less likely to genome modifications, as
evidenced by their high rate of nucleotide sequence conservation
over the time. This may be due to their lifecycle requirement to
replicate in two taxonomically distinct hosts [48–50]. Thus, most
mutations which occur during arboviruses replication appear to
impair viral fitness. In line with these observations, we showed that
modification of the conserved CHIKV residues E1.T101, E2.T12,
E2.G82, and E2.V216 is associated with reduced viral fitness in
vitro and/or in vivo.
After 8 cycles of neutralization/amplification, only partial
CHIKV resistance to mAb 8B10 or 5F10+8B10 was observed.
We then performed 5 additional rounds of neutralization/
amplification while using increasing concentrations of mAb.
However, even after 13 neutralization/amplification rounds under
mAb selective pressure, we did not manage to select a CHIKV
population fully resistant to 8B10 or 5F10+8B10 (data not shown).
It is likely therefore that the mutation(s) required to fully escape
8B10 and 5F10+8B10 mAb give(s) rise to viruses that are unable to
replicate robustly.
Cell-to-cell virus transmission is faster than extra-cellular
spreading and enables viruses to evade the immune response
[31,34,51]. Herpesviruses, flaviviruses, paramyxoviruses, poxvi-
ruses, retroviruses and rhabdoviruses have already been shown to
employ this cell-associated infection route, either exclusively, or in
parallel with extra-cellular viral dissemination [32,34]. Cell-to-cell
transmission seems to be limited to enveloped viruses which exit at
the plasma membrane either by budding or by exocytosis, whereas
lytic viruses disseminate only by extra-cellular transmission
[32,34]. Despite their biological and structural characteristics
making them prone to cell-associated dissemination, alphaviruses
have not previously been shown to transfer directly between cells.
Interestingly, in an earlier report, direct CHIKV transmission
between cells was postulated as a mechanism of antibody escape
since the virus could be detected in cultured cells despite the
presence of anti-CHIKV serum [35]. However, the presence of
newly-infected cells was not demonstrated.
We demonstrate in this report, for the first time, CHIKV direct
cell-to-cell transmission, and further show that this mode of
dissemination is enhanced by the E2.R82G mutation. Interesting-
ly, as the alignment of available CHIKV E2 protein sequences
obtained from GeneBank (data not shown) revealed that the
majority of CHIKV variants contain the residue E2.G82 (and not
E2.R82), we speculate that direct cell-to-cell transmission is
commonly used by CHIKV to disseminate in the presence of
extra-cellular neutralizing antibodies. However, this remains to be
shown with CHIKV isolates containing the residue E2.G82.
Viruses have evolved various mechanisms to disseminate from
cell to cell. Pre-existing cell-cell contacts may be exploited, or
virus-induced new contacts can be established between infected
and uninfected target cells. [32,34,52]. The confocal microscopy
images presented in the current report suggest that CHIKV may
use pre-existing cell-cell contacts, possibly tight junctions, to
transfer directly between cells. Further studies are now warranted
to precisely characterize the mechanism of CHIKV cell-to-cell
transmission.
The fact that CHIKV cell-to-cell transmission is enhanced by
E2.R82G, suggests the involvement of the CHIKV E2 domain A
in this mode of dissemination. Interestingly, the E2 domain A of
both Venezuelan Equine Encephalitis virus and Sindbis virus has
previously been shown to contain residues that are important for
virus binding to cells, notably to heparan sulfate located at the cell
surface [18,53–55]. In this context, we speculate that the mutation
E2.R82G may similarly enhance CHIKV binding to the target
cell.
For the first time, we have identified CHIKV envelope domains
that are recognized by human neutralizing immune responses, and
we have been able to demonstrate direct cell-to-cell transmission of
CHIKV. This mode of dissemination, which protects CHIKV
from neutralizing host antibodies, might play an important role in
establishment of CHIKV persistence. These findings advance our
understanding of CHIKV-human host interactions and will aid
the rational design of future domain-based vaccines against
CHIKV, as well as inform further studies of CHIKV pathogenesis.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
guidelines of the Agri-Food and Veterinary Authority (AVA) and
the National Advisory Committee for Laboratory Animal
Research (NACLAR) of Singapore. All animal procedures were
approved by the Institutional Animal Care and Use Committee
(IACUC) of Biological Research Center, Biomedical Sciences
Institutes, A*STAR, Singapore (IACUC number: #100515).
Cells, antibodies and viruses
Vero cells (ATTC CCL-81) and HEK293T cells (ATCC CRL-
N268) were cultured in DMEM-10% FCS (Gibco-Invitrogen). The
CHIKV-neutralizing human mAb 5F10 and 8B10, the irrelevant
human mAb HA4 (referred as Irr.IgG1), and the CHIKV isolate
CHK/Singapore/11/2008 (referred as CHIKV11) have been
described previously [28].
Selection of 5F10 and 8B10-resistant CHIKV mutants
CHIKV11 (200 PFU) was incubated for 1 h at 37uC with
100 ng/ml 5F10 and/or 8B10 in DMEM-10% FCS. HEK293T
cells were then incubated at 37uC for 1.5 h with mAb/CHIKV
mixtures, prior to being further cultured in DMEM-10% FCS
supplemented with additional mAb as before for 2 days. Cell
supernatants were then collected and their infectious viral titer was
determined by Plaque Assay; 200 PFU of rescued virus was
subjected to a second round of neutralization/amplification in the
presence of the same antibodies as employed in previous steps.
Eight neutralization/amplification rounds were performed in total.
Figure 6. Viral fitness of CHIKV neutralization-escape mutants. (A) Vero cells were infected with plaque-purified CHIKV (MOI=0.1). The
number of PFU within the supernatants was determined by Plaque Assay at various times post-infection. Shown are mean and SEM from 3
independent experiments performed in duplicate. (B) Shown are typical plaque patterns by crystal violet staining at 12 h post-infection. (C) AGR129
mice were inoculated with plaque-purified CHIKV (10
3 PFU). PBS-inoculated mice were used as negative controls. Mice were observed every 12 h to
determine post-infection survival. Shown are the survival curves derived from 3 independent experiments (CHIKV, n=10; Mock infected, n=6). P-
values were determined by Grehan-Breslow-Wilcoxon test and compare CHIKV mutants with CHIKwt. (D) Mice were inoculated with CHIKwt or
5F+8B/E2.R82G (10
3 PFU) and the CHIKV load in serum and liver was quantified 48 h post-infection by TCID50. Shown are mean and SEM for 5 mice
per group. P-values were determined using Mann-Whitney test (*, p,0.05). (E) At 48 h post-infection, the amount of CHIKV (-)RNA in liver was
determined by quantitative RT-PCR. Shown are mean and SEM for 5 mice per group. P-values were determined using Mann-Whitney test (**, p,0.01).
doi:10.1371/journal.ppat.1002390.g006
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Vero cells were infected for 1.5 h with CHIKV (10 PFU/well)
before being washed with PBS and cultured in DMEM-0.25%
agarose for 2 days. Individual CHIKV colonies were then selected
through the agarose layer and amplified separately in Vero cells.
Plaque-purified clonal CHIKV genomes were then sequenced.
Figure 7. Quantification of CHIKV cell-to-cell transmission. CHIKV-infected HEK293T cells (producer cells) were co-cultured with CFSE-labeled
naı ¨ve HEK293T cells (target cells) in the absence or presence of mAb 8B10. (A) The number of infected cells was quantified by flow-cytometry either
immediately (T=0 h), or after 16 h of co-culture (T=16 h). Above each panel are shown the mean number of infected producer (T=0 h) or target
(T=16 h) cells alongside the SEM (5 independent experiments performed in duplicate). P-values were determined using Wilcoxon test, and compare
CHIKwt and 5F+8B/E2.R82G infectivity (*, p,0.05). (B) After 16 h of co-culture, the number of extra-cellular CHIKV particles within the supernatants
was determined by Plaque Assay. Shown are mean and SEM from 5 independent experiments performed in duplicate.
doi:10.1371/journal.ppat.1002390.g007
Figure 8. CHIKV is polarized to sites of cell-cell contact under neutralizing antibody pressure. CHIKV-infected HEK293T cells were co-
cultured with CFSE-labeled naı ¨ve HEK293T cells (green) in the absence or presence of mAb 8B10. After 16 h of co-culture the cells were fixed,
permeabilized, and stained for alphavirus expression (Alexa 647, red). Newly infected target cells appear orange. Magnification: 640 or 680.
doi:10.1371/journal.ppat.1002390.g008
CHIKV Neutralization-Escape Mutants
PLoS Pathogens | www.plospathogens.org 13 December 2011 | Volume 7 | Issue 12 | e1002390Viral sequencing
Viral RNA was extracted from 140 ml supernatant from
CHIKV infected-cells using the QIAamp Viral RNA Mini kit
(Qiagen). For each viral RNA, two independent full-length cDNAs
were synthesized using random hexamers and SuperScript III
First-Strand kit (both from Invitrogen). Purified cDNAs were
PCR-amplified using Taq PCR Master Mix Kit (Qiagen) and
several primer pairs designed to cover the C-E1 CHIKV
polyprotein encoding sequence and to generate ,1000 bp-long
overlapping PCR fragments. PCR fragments were sequenced
(Aitbiotech) and results were analyzed using Lasergene 7 software.
Next-Generation sequencing
A 200 bp cDNA library was synthesized from 56 ng of
extracted CHIK/Irr RNA using the mRNA-seq Sample Prep
Kit (Illumina) according to the manufacturer’s instructions. The
cDNA library was then sequenced using the Illumina GAIIX
genome analyzer (Next Generation Sequencing Core facility,
Genomic Institute of Singapore) at the coverage of 674366.
Unique reads were subsequently aligned with the consensus
sequence encoding CHIKV11 structural proteins (C-E1) using the
Burrows-Wheeler aligner, and site-specific nucleotide frequencies
were determined using SAMtools Pileup.
Plaque Reduction Neutralization test and mAb potency
The Plaque Reduction Neutralization test and determination of
mAb potency were performed as previously described [28].
Binding assays
Immunofluorescence Assay: HEK293T cells were infected with
CHIKV and then fixed as previously described [28]. One mg/ml
mAb or human anti-CHIKV polyclonal plasma (1:200) was added
to either CHIKV-infected or non-infected cells for 1 h at 37uC.
Antibody binding was detected by addition of 2 mg/ml Alexa-488-
labeled mouse anti-human IgG (Invitrogen) followed by fluores-
cence microscopy (NIKON ECLIPSE TS 100) at 1006
magnification. Alternatively, mAb binding to CHIKV-infected
cells was quantified using a Cellomics HCS Reader (Cellomics
ArrayScan, Thermo Fisher Scientific): HEK293T cells were
infected with CHIKV as previously described [28]. At 24 h
post-infection, the cells were washed and fixed overnight with 4%
paraformaldehyde. One mg/ml mAb or human anti-CHIKV
polyclonal plasma (1:200) was added to CHIKV-infected or non-
infected cells for 1 h at 37uC. Antibody binding was detected by
addition of 10 mg/ml Alexa-488-labeled mouse anti-human IgG
(Invitrogen). Cell nuclei were visualized using DAPI staining and
images were captured at 106magnification.
In some experiments, 96-well plates were coated with UV-
inactivated plaque-purified CHIKVs (10
4 PFU/well) for analysis
by ELISA. A range of mAb concentrations (0.1 ng-10 mg/mL)
were added to the wells for 1 h at RT. Bound mAb were detected
using HRP-conjugated goat anti-human IgG (Jackson ImmunoR-
esearch), followed by incubation with 3,39,5,59-tetramethybenzi-
dine substrate (Sigma). The reaction was stopped by addition of
HCl (1 M) and absorbance was measured at 450 nm using the
TECAN Infinite M200 Monochromator Microplate Reader
(TECAN).
In vitro viral fitness analysis
Vero cells were infected with plaque-purified CHIKV mutants
(MOI=0.1) for 1.5 h prior to being cultured in DMEM-10%
FCS. The number of PFU in each supernatant was determined by
Plaque Assay at various times post-infection.
In vivo experiments
AGR129 mice (IFN-a/ß/cR
2/2/2 and RAG-2 deficient, [29])
were used at 8–12 weeks of age and were inoculated intravenously with
10
3CHIKV PFU diluted in 200 ml PBS (or with PBS-alone for control
mice). In survival experiments, mice were observed at 12 h intervals
thereafter. For viral load quantification, mice were bled at 48 h post-
infection, prior to sacrificing them and liver harvesting. Viral load in
sera and homogenized liver supernatants were determined by
measurement, using Vero cells, of tissue cytopathic infectious dose 50
(TCID50) expressed as TCID50/mL and TCID50/g, respectively. In
parallel, total RNA was extracted from 1 g of liver using TRI reagent
(Sigma) according to the manufacturer’s instructions. To quantify
CHIKV (-)RNA copies, 3.6 ng total RNA extracted from liver was
subjected to qRT-PCR as previously described [56].
Co-culture assays
HEK293T cells were infected with CHIKV for 1.5 h
(MOI=0.1), then washed and cultured in DMEM-10% FCS. At
10 h post-infection, naı ¨ve ‘‘target’’ HEK293T cells were labeled
with 10 mM CFSE (Sigma) and 3610
5 labeled ‘‘target’’ cells were
co-seeded into 12-well plates with 3610
5 extensively washed
infected or non-infected ‘‘producer’’ cells. The cells were then co-
cultured in DMEM-10% FCS, supplemented or not with 200 mg/
mL 8B10. At 0 h and 16 h post-co-culture the cells were
harvested, washed and fixed/permeabilized (BD Cytoperm/
Cytofix, BD Biosciences), prior to intracellular staining with
5 mg/mL mouse IgG2a anti-alphavirus (3581) (Santa Cruz
Biotechnology) followed addition of 4 mg/mL Alexa 647-conju-
gated goat anti-mouse IgG (Invitrogen). The proportion of
infected cells was then determined by flow-cytometry (FACSCa-
libur, BD Biosciences). Cell supernatants were also collected in
parallel after 16 h co-culture for analysis by Plaque Assay to
quantify infectious extra-cellular CHIKV. Alternatively, at 14 h
post-infection, 10
5 HEK293T cells were seeded into m-Slide 8 well
plates (Ibidi) with 10
5 CFSE-labeled uninfected cells and then
cultured as described above. After 16 h of co-culture the cells were
washed with PBS, fixed with PBS-4% paraformaldehyde and then
permeabilized in PBS-0.5% Triton X-100. The permeabilized
cells were then stained with 3 mg/mL mouse IgG2a anti-
alphavirus (3581) followed by addition of 3 mg/mL Alexa 647-
conjugated goat anti-mouse IgG (Invitrogen). ProLong Gold
(Invitrogen) was added to the wells and fluorescence was analyzed
using an Olympus FV1000 confocal microscope at 640
magnification (or at 680 in highlighted panels).
Statistical analyses
Data were analyzed using GraphPad Prism 5. The specific
statistical tests used are indicated in the respective figure legends.
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